• Corpus ID: 7233917

Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3.

  title={Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3.},
  author={Sefer Kumandas and Esad Koklu and Hakan G{\"u}m{\"u}ş and Selmin Koklu and Selim Kurtoğlu and Musa Karakukcu and Mehmet Keskin},
  journal={Journal of pediatric endocrinology \& metabolism : JPEM},
  volume={19 4},
OBJECTIVE To examine the effect of carbamezapine and valproate on bone mineral density (BMD), IGF-I and IGFBP-3 levels in children. METHODS The effects of at least 2 years valproic acid and carbamazepine therapy on BMD were evaluated in a cross-sectional and retrospective study. All children were ambulatory, prepubertal, and had normal activity and nutritionally adequate diets. Ambulatory epileptic patients were divided into two groups. Thirty-three patients (group 1; 17 boys, 16 girls; mean… 

Bone metabolism alteration on antiepileptic drug therapy

Serum biochemical changes which indicate predisposition to development of rickets or osteomalacia appear within 90 days of starting carbamazepine or valproic acid monotherapy, however simultaneous supplementation with oral calcium and 25-OHvit D is effective in preventing the development of these adverse biochemical changes.

Bone Mineral Density in Ambulatory Children with Epilepsy

It can be concluded that both enzyme-induced and non enzyme-inducing AEDs decrease bone mineral density (BMD) and alkaline phosphatase (ALP) is affected in ambulatory epileptic children on enzyme- inducing AEDS.

Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients.

Using new generation antiepileptics, LEV monotherapies and polytherapy showed harmful effects on bone but LTG did not.

Evaluation of Bone Metabolism in Children Using Antiseizure Drugs: A Single-Center Experience and Review of the Literature

Physical activity, sun exposure, and calcium intake might be recommended in children treated with ACDs and in combination with additional risk factors monitoring via DXA should be considered.

Bone mineral density in angelman syndrome.